MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia.
about
Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseasesThe role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapyRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceThe clinically relevant pharmacogenomic changes in acute myelogenous leukemiaFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapiesABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?New inhibitors of ABCG2 identified by high-throughput screeningZosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).Flow cytometry of the side population (SP).High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.Discovery of dominant and dormant genes from expression data using a novel generalization of SNR for multi-class problems.P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patientsTargeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.The challenge of exploiting ABCG2 in the clinic.ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patientsThe effect of radiation exposure on multidrug resistance: in vitro and in vivo studies using non-small lung cancer cellsDrug resistance: still a daunting challenge to the successful treatment of AML.DualChip microarray as a new tool in cancer research.Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).Molecular mechanisms of drug resistance in acute myeloid leukaemia.Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia.Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancerABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2.Pharmacogenomics in acute myeloid leukemia.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.Human ABCG2: structure, function, and its role in multidrug resistance.Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy.Nature and uses of fluorescent dyes for drug transporter studies.ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML.ATP-binding casette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers.Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines.3β-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression.ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.Coexpression of Multiple ABC-Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia.
P2860
Q24601963-FEB0EA8C-2AC8-4C7E-A586-29CB1AD0E0DDQ26830005-AE6E013F-A0BF-48F1-8B6B-D5E085C07C13Q26865927-5FA4C80B-8613-46E9-9D77-26D0192742BDQ27014790-AFCB2F0B-875A-4181-9E12-C45F093FA98BQ27851545-DF11AC4A-F8A7-42D4-9AFA-51400D9496B6Q28067499-D4A0FC22-7B64-4B5C-AA0B-32F3EA7765CEQ33281867-3C81F9A0-DED3-4DD4-9DCE-5F65506D90FCQ33311099-E04B52BE-8342-4A1B-BC96-FF7D40E5B77CQ33319637-9965C5BC-4B9C-4CAB-9F5E-9FB8DA6675A7Q33366775-277E8765-A33B-4CA0-A125-1754945D6C69Q33373033-F3EAACEA-6726-4AA1-8AAB-35F042AFD1BFQ33374663-83088C7C-8EBF-45A1-BBDD-671126FCE10BQ33472987-9CDCD4D5-B1D8-4846-9AB2-D2962FBC40C1Q33763765-D0CBFAEE-B914-45D3-85E4-E7A136EE49BEQ33886564-28F3E8B0-EC76-4B2C-8EE0-2FCC3E453B59Q34204238-29661C33-C275-438D-ADB7-73A7BFECC5C0Q34871636-EB30B774-B4C6-4F99-9296-4999BBE6CD22Q34968909-84028FAC-DE46-46FA-8CA0-5D90A82D2176Q35193725-78C711DB-1280-41C5-B92C-AB6CFE65985CQ35267029-D4D8859F-8E5A-499D-B521-BEC537A153CFQ35946969-55095AF3-BDD0-4EB0-919C-4765E6FF5343Q36481097-9C1872E8-1035-4F92-A656-B850BCB1953BQ36771977-3010E465-4150-4E86-BDB9-C6DB7B39D7A3Q36835812-973AA813-3619-4DEF-948E-41CFEA3768B7Q36923079-1BE1F376-DC8A-486D-BB3A-965819A82D20Q37002149-3644CBDC-1B58-4FD6-98D5-32E7520B3472Q37241606-892DD730-AA10-476D-8958-79C384FFFE4CQ37287637-2CF826E3-A795-4ECD-8EBF-64B905764C72Q37610090-3C6555F2-FC82-4B85-9029-2680CCD35C01Q37627876-CF9ACE57-5F8C-4AC5-B5BD-A93063009D79Q37958162-9F5E41E3-F6D7-4636-8A10-A810AAB68E57Q38003156-9F977B2D-A5F2-4878-96C2-BF8472F722A1Q38071981-6AA90D40-E061-4929-8904-51ABC0D65191Q38518912-ACAC1BF7-EF79-4A4A-B249-6A20C60ED452Q38724266-7E24C38D-092D-4245-8BAC-BFA8144CEBB9Q39005733-9EDFCCD0-0200-4F4A-962A-A9D0876F0326Q39278805-DF820C25-35EA-497A-ACE8-5E45E52CD2B4Q39660008-F70D46EF-30D8-433A-AEE3-08BFF0E0D3D8Q40852245-223DC5EB-B10B-4D28-BBA5-5318F0C1396FQ41172549-83F2291A-3AF3-4E33-9A8F-169B5D9BA5F9
P2860
MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
MRP3, BCRP, and P-glycoprotein ...... adult acute myeloid leukemia.
@en
type
label
MRP3, BCRP, and P-glycoprotein ...... adult acute myeloid leukemia.
@en
prefLabel
MRP3, BCRP, and P-glycoprotein ...... adult acute myeloid leukemia.
@en
P2093
P1476
MRP3, BCRP, and P-glycoprotein ...... adult acute myeloid leukemia.
@en
P2093
Anne Marie Faussat
Christophe Marzac
Driss Chaoui
Hamid Morjani
Jean-Pierre Marie
Jean-Yves Perrot
Lydia Sayada
Ollivier Legrand
Ruoping Tang
Zineb Benderra
P304
P356
10.1158/1078-0432.CCR-04-1895
P407
P577
2005-11-01T00:00:00Z